Myelodysplastic Syndrome with Low Blasts — Rankings

Myelodysplastic Syndrome with Low Blasts — Rankings · CancerIndex

Rankings

Why this rank?

4 current ranking rows (latest year per scope). Each row lists the scope, the formula version, the value and the exact inputs that produced it.

Metric	Scope	Rank / eligible	Δ	Value	Percentile	Confidence	Formula	Generated	Inputs
Publications, last 12 months	World · both sexes · all ages · latest · all malignant entities	#1196 / 2,294	=	6 count	47.9	Medium confidence	ci-pubs-12m-v1	Sep 30, 2026	show formula: literature_counts.count WHERE window_key = 12m counter publicationCount12m computedAt 2026-09-30T06:00:02.308Z inputs hash b1963bee32e72b8b6e51efec Trace lineage (admin)
Publications, last 5 years	World · both sexes · all ages · latest · all malignant entities	#1546 / 2,873	=	15 count	46.2	Medium confidence	ci-pubs-5y-v1	Sep 30, 2026	show formula: literature_counts.count WHERE window_key = 5y (query stored per row) counter publicationCount5y computedAt 2026-09-30T06:00:02.308Z inputs hash 7b01855837dd178dff17a0c3 Trace lineage (admin)
Active clinical trials	World · both sexes · all ages · latest · all malignant entities	#1186 / 1,654	=	1 count	28.3	Medium confidence	ci-active-trials-v1	Sep 30, 2026	show formula: COUNT(DISTINCT trial) FROM trial_conditions JOIN clinical_trials WHERE cancer_id IN descendants(cancer) AND study_type = INTERVENTIONAL AND overall_status IN (RECRUITING, NOT_YET_RECRUITING, ENROLLING_BY_INVITATION, ACTIVE_NOT_RECRUITING) counter activeTrialCount computedAt 2026-09-30T06:00:02.308Z inputs hash d8f333d5bfdbadb41c05f9e2 Trace lineage (admin)
Recruiting clinical trials	World · both sexes · all ages · latest · all malignant entities	#893 / 1,284	=	1 count	30.5	Medium confidence	ci-recruiting-trials-v1	Sep 30, 2026	show formula: COUNT(DISTINCT trial) … overall_status = RECRUITING AND study_type = INTERVENTIONAL counter recruitingTrialCount computedAt 2026-09-30T06:00:02.308Z inputs hash 00002505dcded3e0217a182d Trace lineage (admin)

Computed Ranks are competition ranks (ties share a rank). Percentile = share of eligible entities ranked at or below this one in the ranking direction.

"Deadliest" is ambiguous: annual deaths, age-standardized mortality rate, mortality-to-incidence ratio and 5-year survival rank cancers differently. CancerIndex publishes each as a separate metric.

Why this rank?

Research gap